TUHURA BIOSCIENCES INC

NASDAQ: HURA (TuHURA Biosciences, Inc.)

Last update: 24 Jan, 4:13AM

4.62

-0.15 (-3.14%)

Previous Close 4.77
Open 4.68
Volume 121,720
Avg. Volume (3M) 317,667
Market Cap 195,354,384
Price / Book 11.22
52 Weeks Range
2.84 (-38%) — 14.60 (215%)
Earnings Date 12 Feb 2025 - 17 Feb 2025
Diluted EPS (TTM) -0.960
Total Debt/Equity (MRQ) 1.67%
Current Ratio (MRQ) 3.00
Operating Cash Flow (TTM) -15.63 M
Levered Free Cash Flow (TTM) -15.19 M
Return on Assets (TTM) -90.68%
Return on Equity (TTM) -332.67%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bearish
Biotechnology (Global) Bearish Bearish
Stock TuHURA Biosciences, Inc. Bearish -

AIStockmoo Score

-0.6
Analyst Consensus -0.5
Insider Activity NA
Price Volatility -2.0
Technical Moving Averages 2.5
Technical Oscillators -2.5
Average -0.63

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
HURA 195 M - - 11.22
ASND 11 B - - -
CNTA 2 B - - 4.36
GYRE 725 M - 401.50 11.27
BCAX 631 M - - 1.37
DNTH 561 M - - 1.77

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Sector Healthcare
Industry Biotechnology
% Held by Insiders 41.96%
% Held by Institutions 8.43%

Ownership

Name Date Shares Held
Cyndeo Wealth Partners, Llc 31 Dec 2024 10,627
52 Weeks Range
2.84 (-38%) — 14.60 (215%)
Median 12.00 (159.74%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 16 May 2025 12.00 (159.74%) Buy 3.92
03 Apr 2025 12.00 (159.74%) Buy 3.40

No data within this time range.

Date Type Details
09 Jun 2025 Announcement FDA Removes Partial Clinical Hold on TuHURA Biosciences' Phase 3 Accelerated Approval Trial for IFx-2.0 in Advanced or Metastatic Merkel Cell Carcinoma
03 Jun 2025 Announcement TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional $3.0 Million in Warrant Exercise Proceeds to Advance Its Pipeline of Novel Treatments to Overcome Primary Resistance to Cancer Immunotherapy
02 Jun 2025 Announcement TuHURA Biosciences Presents IFx-Hu2.0 Trial-in-Progress Poster at the 2025 American Society of Clinical Oncology Annual Meeting
15 May 2025 Announcement TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
13 May 2025 Announcement TuHURA Biosciences, Inc. to Present at the 3rd Annual H.C. Wainwright BioConnect Conference
05 May 2025 Announcement TuHURA Biosciences, Inc. Initiates Phase 1b/2a Study of IFx-Hu2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Metastatic Merkel Cell Carcinoma of Unknown Primary Origin (MCCUP)
28 Apr 2025 Announcement TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual ...
08 Apr 2025 Announcement TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting
07 Apr 2025 Announcement TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
01 Apr 2025 Announcement TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria